UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

September 27, 2011
Date of Report (Date of earliest event reported)

GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

NEVADA	000-32877	04-3562325
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of principal executive offices) (Zip Code)

(617) 559-0033
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Peter G. Traber, M.D., President and Chief Executive Officer of Galectin Therapeutics Inc. ("Company"), presented a corporate overview contained in the slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") on September 28, 2011.

The information in this Report is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Corporate overview presentation slides - dated September 27, 2011.
99.2 Galectin Therapeutics Inc. press release dated September 29, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ ANTHONY D. SQUEGLIA
Anthony D. Squeglia
Chief Financial Officer

Date: September 29, 2011

EXHIBIT INDEX

Exhibit No.:

99.1	Corporate overview presentation slides, dated September 27, 2011.
99.2	Galectin Therapeutics Inc. press release dated September 29, 2011.

Galectin Therapeutics

Company Update

September 27, 2011

OTC: GALT

Forward Looking Statements

This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Recent Highlights

- March 2011: New CEO
- May 2011: Announced new strategic priorities, new web site
- May 2011: Name changed to Galectin Therapeutics (Formally Pro-Pharmaceuticals)
- July 2011: Analyst coverage initiated by Shiv Kapoor of Morgan Joseph TriArtisan
- August 2011: Analyst coverage initiated by Vernon Bernardino of Dawson James Securities
- September 2011: Presentation at Rodman & Renshaw Conference, New York, New York

Galectin Therapeutics Highlights

- Leader in galectin science
  - Pipeline of carbohydrate-based drug compounds that inhibit galectins
- Liver fibrosis program goal to be first therapy for this indication
  - Target validated in convincing pre-clinical data
  - Clinical trials expected to begin in 2012
- Cancer Therapy
  - Galectin inhibitor added to chemotherapy
  - Cancer immunotherapy program activates patient's own immune system to kill tumor cells

Galectin Proteins Are Important In Disease Pathogenesis



Secreted Galectin Proteins

1. Bind to cell surface and matrix glycoproteins (galactose residues)
2. Modulate cell signaling
3. Promote cell-cell interactions
4. Promote cell-matrix interactions

Markedly Increased in:

1. Fibrosis
2. Cancer
3. Inflammation

PROMOTE PATHOLOGY

Our Galectin Inhibitors Are Novel Carbohydrate-Based Drug Compounds



- Target secreted galectins and those associated with cell membrane
- Strong binding to multiple galectin proteins and multiple galectins per drug molecule
- High molecular weight allows long exposure to galectin containing compartment
- Low toxicity potential as a carbohydrate with no toxic metabolites
- Low manufacturing costs
- Strong patent protection with no licensing encumbrance
- Two major classes of compounds under development: GM-CT and GR-MD

We Are The Leaders In Galectin Inhibitor Drug Development

- Only company with galectin inhibitors in clinical development
- Published authoritative books in the field





Galectins Are Involved In The Pathogenesis Of Many Diseases

Galectins implicated in:

- **Fibrosis of organs**
- **Nearly all cancers**
- Heart failure
- Ischemic cardiovascular and cerebrovascular disease
- Arthritis
- Allergic disease
- Eczema and skin inflammation
- Inflammatory bowel disease
- Eye inflammation
- Inflammatory and autoimmune disorders
- Response to infections
- Kidney disease

So, How Do We Choose Diseases For Drug Development?

Treat important diseases where:

- Galectins are proven important in the mechanism of disease
- There are serious, life threatening consequences to patients
- There are no, few, or ineffective therapies
- Rapid development pathways are possible

Disease Area Development Programs



Disease Area Development Programs



Many Diseases Lead To Liver Fibrosis And Cirrhosis With Serious Medical Consequences



Healthy

Cirrhosis

- Hepatitis C (57%)
- Alcoholic liver disease (24%)
- Non-alcoholic fatty liver (9.1%)
- Hepatitis B (4.4%)
- Miscellaneous (5.5%)

Source: Burden of liver disease in the United States: Summary of a workshop. American Association for the Study of Liver Disease, May 2001

Liver Cirrhosis Is A Major Problem In The United States

The ONLY current therapy is liver transplantation

Transplants	**(6,291*)**
Wait List	**(17,000**)**
Death	**(44,677#)**
Cirrhosis	**(400,000##)**

Millions of people with liver disease that may progress to cirrhosis



* Performed in US in 2010 (UNOS)

* * Prevalence in US 2010 (UNOS)

#Deaths in 1998 (AASLD Workshop, 2001)

##Prevalence in US 1976-1980 (NIDDK)

Galectin-3 Is A Critical Target For Therapy of Liver Fibrosis

Key Evidence:

1. Galectin-3 is produced in large amounts by human fibrotic liver
2. Galectin-3 is essential in mice for the development of liver fibrosis
3. Galectin inhibitors block production of fibrogenic markers in the key human cell responsible for liver fibrosis
4. Galectin inhibitors reverse experimental fibrosis in rats

Galectin Inhibitors Effectively Treat Liver Fibrosis in Rats

Liver Fibrosis, induced by injection of chemical toxin for 8 weeks



Regression of Fibrosis after 4 weeks of treatment with GR-MD-01



Summary Of Development Program Rationale In Liver Fibrosis

- Liver fibrosis represents a very large unmet medical need
- Galectin-3 protein is proven target
- Drugs reverse liver fibrosis in animals and show efficacy in human cell culture models of fibrosis
- Non toxic drugs with little likelihood of drug interactions
- Rapid clinical development pathways
- Initial indication provides opportunity for orphan disease status, fast track, priority review, and potentially accelerated approval

Development Program & Markets

- Initial Indication: Post transplant recurrent Hepatitis C with fibrosis
  - Focus of first phase II clinical trial
  - Orphan disease designation possible
- Additional peri-transplant indications:
  - Established cirrhosis of various etiologies but not eligible for transplantation
  - Established cirrhosis of various etiologies, on transplant list
- Expansion of indications
  - Non-alcoholic fatty liver disease (NASH)
  - Viral hepatitis C and B with fibrosis
  - Alcoholic fibrosis

Fibrosis Pipeline: Drug Advancement December 2011

	Pre-Clinical	Phase 1	Phase 2	Phase 3	Registration Submitted
Liver Fibrosis					
GM-CT-01					
GM-CT-02					
GR-MD-01					
GR-MD-02					

More advanced than typical pre-clinical development program:

Efficacy shown in human cells as well as animals

Proven safety in animals and humans (GM-CT-01)

Low potential for toxicity for all compounds

Low potential for drug interactions

Fibrosis Clinical Program (First Indication Clinical Trials)



Pre-IND Meeting
Submit IND
Initiate P-I
Initiate P-II

Disease Area Development Programs



Roles Of Secreted Galectins In Cancer

The vast majority of cancers secrete large amounts of galectins



- Galectins impact cancer growth at many points
- Interfering with galectin function has been shown to have beneficial effects
- Galectin Therapeutics has proprietary compounds that leverage this benefit

Phase 2 Clinical Trial Performed in Metastatic Colorectal Cancer (DAVFU-003)

- Phase 2 trial of 5-FU plus GM-CT-01 in line 3/4 therapy of metastatic colorectal cancer
- Twenty (20) patients enrolled who all had 3 to 4 previous courses of chemotherapy, including 5-FU and biologicals
- Overall median survival was 6.7 months.
- In similar patients, Erbitux® had a 6.1 month survival compared to 4.6 months with no therapy
- Suggests efficacy of regimen

GM-CT-01 Reduces 5-FU Chemotherapy Related Side Effects

Event in percent of patients (%)	5-FU/LV Studies	5-FU+GM-CT-01
	N=1128	N=57
Adverse Events	Grade 3-4 (%)	Grade 3-4(%)
Diarrhea	12-40	0
Nausea/Vomiting	4-9	<2
Mucositis	17-22	<2
Neutropenia/ Leukopenia	7-67	<2

Simultaneous improved efficacy with reduction in side effects of standard chemotherapy would be desirable in cancer therapeutics

Data on 5-FU+GM-CT-01 compiled from patients receiving full dose therapy in studies DAVFU-001, 003, 006, and 007

Development Approach In Colorectal Cancer

- Studies demonstrate potential utility of galectin inhibitors in combination with chemotherapy in cancer
- FDA has confirmed that preclinical and clinical data are adequate to proceed with large clinical trials
- Our colorectal cancer program remains active, but we are deferring new clinical trials pending data from the tumor immunology clinical trial that may improve the design of future studies
- More rapid international registration is an approach that may provide revenue to support development programs and gain additional clinical experience with GM-CT-01

Registration And Marketing GM-CT-01 In Colombia And Latin America

- The government of Colombia, and oncology key opinion leaders in that country, expressed an interest in making GM-CT-01 available for use in Colombia for patients with metastatic colorectal cancer
- Equally interested in the increased tumor efficacy and reduction in 5-FU related side effects
- Our partner Pro-Caps has submitted a marketing application to INVIMA (FDA equivalent) and has indicated our clinical data should be sufficient for approval
- With approval, Pro-Caps expects sales to begin in 2012
- Upon success in Colombia, we have the opportunity to seek approval in other Latin American countries (reciprocity with 12 other countries)

Disease Area Development Programs



Enhancing Anti-Tumor Immunity Is A Promising Effect Of Blocking Galectins



- **Tumor cell invasion:** extracellular matrix adhesion & detachment
- **Stromal cell function**
- **Metastasis:** cell invasion and migration
- **Angiogenesis**
- **Tumor immunity**

Blocking Galectins Enhances Tumor Killing By Immune System



Studies done in collaboration with Ludwig Institute, Brussels, Belgium

GM-CT-01 Restores Ability of Immune Cells to Kill Tumor Cells



Effectors:
CD8+ T cells cultured in medium treated for 20h
Targets:
P815 cells loaded with anti-CD3+ cold K562

Effectors:
CD8+ T cells cultured in medium with GM-CT-01 for 20h
Targets:
P815 cells loaded with anti-CD3+ cold K562

GM-CT-01 In Tumor Immunotherapy

- A Phase 1/2 study is scheduled to begin in Q4 2011
  - IMPD (Investigational Medicinal Product Dossier) was submitted to the EMA (European Medicines Agency) on September 20, 2011
  - Patients with advanced metastatic melanoma
  - Treatment Regimen:
    - Tumor-specific peptide vaccination (previously tested)
    - GM-CT-01 administered between peptide vaccinations
  - Primary endpoint: Partial or complete response
  - Historical controls who received same peptide vaccine
  - Galectin Therapeutics provides study drug
  - The Ludwig Institute and Cancer Center funds Stage 1 of the trial
  - Trial conducted in 6 centers in Europe (Belgium, France, Luxembourg)

Melanoma Clinical Trial Design (I)

Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma



Melanoma Clinical Trial Design (II)

Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma



Regimen of GM-CT-01 in Melanoma Trial Versus Colorectal Cancer Trial



Development Program In Cancer Immunotherapy

- Galectin proteins secreted by tumor cells are directly responsible for inhibiting the ability of immune cells to kill tumors
- GM-CT-01 restores the ability of immune cells to kill tumor cells
- Initial clinical trial for treatment of metastatic malignant melanoma
- Market for tumor vaccines is expected to grow to $7B by 2015
- Potential important therapy for many cancers

Pipeline

	Pre-Clinical	Phase 1	Phase 2	Phase 3	Registration Submitted
Colorectal Cancer					
GM-CT-01					
• International (Colombia)					
• United States					
Tumor Vaccine					
GM-CT-01					
Liver Fibrosis					
GM-CT-01					
GM-CT-02					
GR-MD-01					
GR-MD-02					

Catalyst Milestones

- Fibrosis Program
  - Complete pre-clinical assessment and announce drug or drugs to take into clinical development: December 2011
  - Commence phase 2 trial Q2 2012 with top line results Q2/Q3 2013 (GM-CT-01)
  - Commence phase 1 trial Q3 2012 and phase 2 trial Q4 2012 with top line results Q4 2013 (GR-MD series)
- Tumor Immunology Program
  - Commence phase 1/2 trial Q4 2011
  - Top line results on first stage second half of 2012
- Chemotherapy Program
  - Colombia final approval to market GM-CT-01 by Q2 2012
  - Sales initiated 2012

Galectin Therapeutics Highlights

- Leader in galectin science
  - Pipeline of carbohydrate-based drug compounds that inhibit galectins
- Liver fibrosis program goal to be first therapy for this indication
  - Target validated in convincing pre-clinical data
  - Clinical trials expected to begin in 2012
- Cancer Therapy
  - Galectin inhibitor added to chemotherapy
  - Cancer immunotherapy program activates patient's own immune system to kill tumor cells

Galectin Therapeutics

Thank You

OTC: GALT

Galectin Therapeutics Posts New Corporate Presentation Video to its Website

Highlights Leadership Position Developing Galectin-Inhibiting Therapeutics to Treat Fibrosis & Cancer

Newton, MA – September 29, 2011 – Galectin Therapeutics Inc. (OTC: GALT) today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer. The video is narrated by Dr. Peter Traber, the Company's President, CEO and Chief Medical Officer.

"We continue to build the foundation for the development of our carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function," said Dr. Traber. "Our GM and GR series of compounds have demonstrated the ability to arrest and reverse liver fibrosis in pre-clinical studies and we are conducting additional studies to define the best compounds to take into clinical trials in 2012. There are currently no treatment options for liver fibrosis except liver transplantation.

"In our cancer chemotherapy program, we are awaiting review of the application for marketing approval in Colombia, South America for the use of GM-CT-01 in combination with 5-FU for metastatic colorectal cancer. We expect GM-CT-01 will be commercialized by our partner Pro-Caps in Colombia, pending regulatory approval in that country. We plan to make important progress in our cancer immunotherapy program as we expect The Ludwig Institute of Cancer Research in Brussels to initiate a Phase I/II clinical trial this year of our GM-CT-01 compound with their cancer vaccine in patients with metastatic melanoma. An IMPD (Investigational Medicinal Product Dossier) for this trial has been submitted to the EMA (European Medicines Agency). GM-CT-01 has demonstrated robust reactivation of tumor infiltrating T-cells in pre-clinical trials, an exciting new area of cancer immunotherapy."

Galectin Therapeutics Portfolio Overview

Galectin Therapeutics is focusing its galectin inhibitor development efforts in two key disease areas: fibrosis and cancer.

- Liver Fibrosis: The Company is developing galectin inhibitors to treat liver fibrosis and the later stage of cirrhosis. Galectin Therapeutics candidates have demonstrated the ability to arrest and reverse liver fibrosis in pre-clinical studies.
- 45,000 deaths from cirrhosis occurred last year in the United States of which only 6,200 of the approximately 400,000 U. S. cirrhosis patients received life saving liver transplants. Liver fibrosis is a disease with no current treatment options except liver transplantation.

Galectin Therapeutics' efforts in cancer encompass two distinct programs, cancer immunotherapy and chemotherapy.

- Cancer Immunotherapy: Recent experiments by The Ludwig Institute of Cancer Research in Brussels, Belgium indicated that GM-CT-01 reactivates T-cell-dependent tumor cell killing that had been turned off by galectins secreted by cancer cells. The Ludwig Institute is planning a Phase 1/2 trial of GM-CT-01 for patients with advanced metastatic melanoma. Patients will receive a tumor-specific peptide vaccination combined with multiple systemic and intra-tumor doses of GM-CT-01 following the second month and subsequent month's vaccine administration.
- Cancer Chemotherapy: The Company is currently awaiting review of its application for marketing approval in Colombia, South America for the use of GM-CT-01 in combination with 5-FU for metastatic colorectal cancer. GM-CT-01 will be commercialized by Galectin Therapeutics' partner in Colombia, Pro-Caps, pending regulatory approval in Colombia.

About Galectin Therapeutics

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact: Anthony D. Squeglia, Chief Financial Officer, 617.559.0033, squeglia@galectintherapeutics.com